CEACAM1 Is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Clear Cell Renal Cell Carcinoma

Table 1

Clinical characteristics of the ccRCC patients in the study.

Characteristics	Low expression of CEACAM1 (<3.578)	High expression of CEACAM1 (>3.578)	value
	269	270
T status, (%)			<0.001
T1	117 (21.7%)	161 (29.9%)
T2	40 (7.4%)	31 (5.8%)
T3	102 (18.9%)	77 (14.3%)
T4	10 (1.9%)	1 (0.2%)
N status, (%)			0.293
N0	125 (48.6%)	116 (45.1%)
N1	11 (4.3%)	5 (1.9%)
M status, (%)			0.009
M0	202 (39.9%)	226 (44.7%)
M1	50 (9.9%)	28 (5.5%)
Pathologic stage, (%)			0.002
Stage I	115 (21.5%)	157 (29.3%)
Stage II	32 (6%)	27 (5%)
Stage III	68 (12.7%)	55 (10.3%)
Stage IV	53 (9.9%)	29 (5.4%)
Gender, (%)			<0.001
Female	70 (13%)	116 (21.5%)
Male	199 (36.9%)	154 (28.6%)
Age, (%)			0.464
≤60	139 (25.8%)	130 (24.1%)
>60	130 (24.1%)	140 (26%)
Histologic grade, (%)			<0.001
G1	3 (0.6%)	11 (2.1%)
G2	101 (19%)	134 (25.2%)
G3	112 (21.1%)	95 (17.9%)
G4	50 (9.4%)	25 (4.7%)
Laterality, (%)			0.545
Left	130 (24.2%)	122 (22.7%)
Right	139 (25.8%)	147 (27.3%)
Primary therapy outcome, (%)			0.045
PD	9 (6.1%)	2 (1.4%)
SD	2 (1.4%)	4 (2.7%)
PR	0 (0%)	2 (1.4%)
CR	58 (39.5%)	70 (47.6%)
Age,			0.745

T: tumor size; N: lymph node; M: metastasis; PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response.